In an attempt to help physicians and patients weigh the risks and benefits of the available options for treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ, researchers have developed a new prediction tool that calculates a patient's individualized risk for recurrence five and ten years after surgery.